ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.

about

ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment.

Item

http://www.wikidata.org/entity/Q39032553

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@en

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@nl

type

Item

label

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@en

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@nl

prefLabel

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@en

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@nl

P1476

ALK inhibitors of bis-ortho-al ...... riazines for cancer treatment.

@en

P2093

Chi Hoon Park

http://www.w3.org/2001/XMLSchema#string

Chong Hak Chae

http://www.w3.org/2001/XMLSchema#string

Chong Ock Lee

http://www.w3.org/2001/XMLSchema#string

Eun Hye Yang

http://www.w3.org/2001/XMLSchema#string

Heung Kyoung Lee

http://www.w3.org/2001/XMLSchema#string

Hyeon Ji Lee

http://www.w3.org/2001/XMLSchema#string

Hyeonjeong Choe

http://www.w3.org/2001/XMLSchema#string

Hyoung Rae Kim

http://www.w3.org/2001/XMLSchema#string

Jeong In Yun

http://www.w3.org/2001/XMLSchema#string

Kwangho Lee

http://www.w3.org/2001/XMLSchema#string

P2860

The biology and treatment of EML4-ALK non-small cell lung cancer

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

P2888

s12272-013-0323-z

P304

1130-1138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12272-013-0323-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Imran Ali

Jae-Kyung Jung

P577

2014-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259826509

http://www.w3.org/2001/XMLSchema#string

P698

24446111

http://www.w3.org/2001/XMLSchema#string